Manas Pustake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manas Pustake has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Sushant Mane
Centre of Excellence for Pediatric TB, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India
9 shared publicationsPurushottam Giri
Department of Community Medicine, IIMSR Medical College, Badnapur, Jalna, Maharashtra, India
8 shared publicationsMohammad Arfat Ganiyani
Department of Internal Medicine, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India
7 shared publications- Mohammad Arfat Ganiyani
Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
6 shared publications Abhizith Deoker
Department of Internal Medicine Texas Tech University Health Science Center El Paso El Paso Texas USA
3 shared publicationsCharmi Gandhi
Department of Internal Medicine, Grant Government Medical College and Sir J.J. Group of Hospitals, Byculla, Mumbai, India
3 shared publications
Latest Publications
- 28 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e271351
Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association
Central retinal artery occlusion (CRAO) is a vision-threatening vascular emergency that often causes permanent monocular visual loss. We report a woman in her late seventies with metastatic hormone receptor-positive, HER2-negative breast cancer and multiple myeloma who developed sudden, painless right monocular vision loss while receiving long-term abemaciclib and lenalidomide. Funduscopic examination showed diffuse retinal whitening, attenuated retinal arterioles and a cherry-red spot, confirming CRAO. She presented approximately 20 hours after symptom onset, outside the window for hyperacute intervention and severe visual impairment persisted. Evaluation showed severe hypertension and extensive cardiovascular comorbidity but no high-grade carotid stenosis, large-vessel occlusion or definite cardiac embolic source. Abemaciclib and lenalidomide have each been associated predominantly with venous thromboembolism. Given the patient’s multiple vascular and malignancy-related risk factors, a treatment-related contribution, including a possible synergistic interaction, cannot be excluded.
- 28 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e271351
Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association
Central retinal artery occlusion (CRAO) is a vision-threatening vascular emergency that often causes permanent monocular visual loss. We report a woman in her late seventies with metastatic hormone receptor-positive, HER2-negative breast cancer and multiple myeloma who developed sudden, painless right monocular vision loss while receiving long-term abemaciclib and lenalidomide. Funduscopic examination showed diffuse retinal whitening, attenuated retinal arterioles and a cherry-red spot, confirming CRAO. She presented approximately 20 hours after symptom onset, outside the window for hyperacute intervention and severe visual impairment persisted. Evaluation showed severe hypertension and extensive cardiovascular comorbidity but no high-grade carotid stenosis, large-vessel occlusion or definite cardiac embolic source. Abemaciclib and lenalidomide have each been associated predominantly with venous thromboembolism. Given the patient’s multiple vascular and malignancy-related risk factors, a treatment-related contribution, including a possible synergistic interaction, cannot be excluded.
- 9 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e268557
Secondary thrombotic thrombocytopenic purpura with features of Evans syndrome in a patient with SLE
A female in her early 40s with systemic lupus erythematosus (SLE) and prior immune thrombocytopenic purpura presented with dizziness, dyspnoea, haematuria and fatigue. Investigations revealed a life-threatening thrombotic microangiopathy triad (platelets 3000/µL, microangiopathic haemolytic anaemia, acute kidney injury) and the strongly positive Coombs test with haemolysis markers supported autoimmune haemolysis in addition to microangiopathic haemolysis. Together with her prior history of immune thrombocytopenia, these findings are consistent with an Evans syndrome overlap, though consumptive thrombocytopenia from thrombotic thrombocytopenic purpura (TTP) could not be excluded. There was evidence of SLE vasculitis. Despite diagnostic overlap obscuring TTP, empiric plasma exchange (PLEX), steroids and rituximab induced rapid haematologic and clinical recovery. Days later, severe ADAMTS13 deficiency (<0.03 IU/mL) confirmed SLE-associated secondary TTP. This case highlights the critical need for empiric PLEX in suspected TTP when possible Evans syndrome complicates SLE and the efficacy of combined immunomodulation targeting both entities.
- 9 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e268557
Secondary thrombotic thrombocytopenic purpura with features of Evans syndrome in a patient with SLE
A female in her early 40s with systemic lupus erythematosus (SLE) and prior immune thrombocytopenic purpura presented with dizziness, dyspnoea, haematuria and fatigue. Investigations revealed a life-threatening thrombotic microangiopathy triad (platelets 3000/µL, microangiopathic haemolytic anaemia, acute kidney injury) and the strongly positive Coombs test with haemolysis markers supported autoimmune haemolysis in addition to microangiopathic haemolysis. Together with her prior history of immune thrombocytopenia, these findings are consistent with an Evans syndrome overlap, though consumptive thrombocytopenia from thrombotic thrombocytopenic purpura (TTP) could not be excluded. There was evidence of SLE vasculitis. Despite diagnostic overlap obscuring TTP, empiric plasma exchange (PLEX), steroids and rituximab induced rapid haematologic and clinical recovery. Days later, severe ADAMTS13 deficiency (<0.03 IU/mL) confirmed SLE-associated secondary TTP. This case highlights the critical need for empiric PLEX in suspected TTP when possible Evans syndrome complicates SLE and the efficacy of combined immunomodulation targeting both entities.
- Open Access
- 29 June 2026
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 14
Amelanotic Gastric Metastases From Melanoma Presenting as Gastrointestinal Bleeding Shortly After Diagnosis: A Case Report
Melanoma is an aggressive malignancy with a high propensity for metastasis; however, clinically apparent involvement of the gastrointestinal tract is uncommon. We report a case of metastatic melanoma involving the stomach that presented as gastrointestinal bleeding shortly after initial diagnosis. A patient with recently diagnosed melanoma with nodal metastasis presented with melena and symptomatic anemia. Esophagogastroduodenoscopy revealed multiple gastric mucosal lesions that were notably amelanotic, lacking the characteristic pigmentation typically associated with melanoma. Histopathological and immunohistochemical evaluation confirmed metastatic melanoma, and imaging findings were concerning for advanced disease. The presence of pneumatosis raised suspicion for mucosal compromise and possible early perforation, highlighting the potential severity of gastrointestinal involvement. Gastrointestinal metastases from melanoma are often clinically silent and may present with nonspecific symptoms, leading to delayed diagnosis. This case is notable for early symptomatic presentation and the presence of amelanotic lesions, which may be easily overlooked during endoscopic evaluation. The absence of pigmentation can pose a diagnostic challenge and requires a high index of suspicion in patients with a history of melanoma. Early endoscopic evaluation and tissue diagnosis are essential for timely recognition and management. Clinicians should maintain a high index of suspicion for gastrointestinal metastases in melanoma patients presenting with unexplained anemia or bleeding, even in the absence of classic endoscopic features.
- 29 June 2026
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 14
Open AccessAmelanotic Gastric Metastases From Melanoma Presenting as Gastrointestinal Bleeding Shortly After Diagnosis: A Case Report
Melanoma is an aggressive malignancy with a high propensity for metastasis; however, clinically apparent involvement of the gastrointestinal tract is uncommon. We report a case of metastatic melanoma involving the stomach that presented as gastrointestinal bleeding shortly after initial diagnosis. A patient with recently diagnosed melanoma with nodal metastasis presented with melena and symptomatic anemia. Esophagogastroduodenoscopy revealed multiple gastric mucosal lesions that were notably amelanotic, lacking the characteristic pigmentation typically associated with melanoma. Histopathological and immunohistochemical evaluation confirmed metastatic melanoma, and imaging findings were concerning for advanced disease. The presence of pneumatosis raised suspicion for mucosal compromise and possible early perforation, highlighting the potential severity of gastrointestinal involvement. Gastrointestinal metastases from melanoma are often clinically silent and may present with nonspecific symptoms, leading to delayed diagnosis. This case is notable for early symptomatic presentation and the presence of amelanotic lesions, which may be easily overlooked during endoscopic evaluation. The absence of pigmentation can pose a diagnostic challenge and requires a high index of suspicion in patients with a history of melanoma. Early endoscopic evaluation and tissue diagnosis are essential for timely recognition and management. Clinicians should maintain a high index of suspicion for gastrointestinal metastases in melanoma patients presenting with unexplained anemia or bleeding, even in the absence of classic endoscopic features.
- Open Access
The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30–40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood. Methods: We conducted a retrospective cohort study of patients with metastatic non-clear-cell RCC. Patients were stratified by receipt of CN. Baseline demographic, clinical, histologic, and metastatic site variables were collected. Overall survival was analyzed using Kaplan–Meier methods and compared with the log-rank test. Cox proportional hazards regression was performed to identify independent predictors of survival, including CN, systemic therapy, year of diagnosis, histology, and metastatic sites. Results: Among 2753 patients with metastatic nccRCC, 1654 (60.1%) underwent CN and 1099 (39.9%) did not undergo CN. The 2-year and 5-year OS rates were 35.52% and 19.22% in the CN group versus 18.53% and 7.47% in the non-CN group (p < 0.001). In the doubly robust IPTW-weighted multivariable Cox regression analysis, CN was associated with improved overall survival, corresponding to a 40% lower risk of death compared with no CN (HR 0.60, 95% CI 0.54–0.66; p < 0.001). Additionally, more recent treatment eras were associated with progressively improved overall survival, with patients diagnosed between 2015 and 2017 and 2018 onward demonstrating significantly improved OS compared with those diagnosed between 2004 and 2014. Conclusions: Our study demonstrates that CN was associated with improved OS in patients with non-clear-cell mRCC by reducing the risk of death by 40% after adjusting for baseline characteristics. These findings emphasize the role of CN even in the IO-TKI era for the management of patients with non-clear-cell mRCC. However, these findings should be interpreted in the context of the retrospective study design, potential selection bias, and lack of granular systemic therapy data within the NCDB.
Open AccessThe Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30–40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood. Methods: We conducted a retrospective cohort study of patients with metastatic non-clear-cell RCC. Patients were stratified by receipt of CN. Baseline demographic, clinical, histologic, and metastatic site variables were collected. Overall survival was analyzed using Kaplan–Meier methods and compared with the log-rank test. Cox proportional hazards regression was performed to identify independent predictors of survival, including CN, systemic therapy, year of diagnosis, histology, and metastatic sites. Results: Among 2753 patients with metastatic nccRCC, 1654 (60.1%) underwent CN and 1099 (39.9%) did not undergo CN. The 2-year and 5-year OS rates were 35.52% and 19.22% in the CN group versus 18.53% and 7.47% in the non-CN group (p < 0.001). In the doubly robust IPTW-weighted multivariable Cox regression analysis, CN was associated with improved overall survival, corresponding to a 40% lower risk of death compared with no CN (HR 0.60, 95% CI 0.54–0.66; p < 0.001). Additionally, more recent treatment eras were associated with progressively improved overall survival, with patients diagnosed between 2015 and 2017 and 2018 onward demonstrating significantly improved OS compared with those diagnosed between 2004 and 2014. Conclusions: Our study demonstrates that CN was associated with improved OS in patients with non-clear-cell mRCC by reducing the risk of death by 40% after adjusting for baseline characteristics. These findings emphasize the role of CN even in the IO-TKI era for the management of patients with non-clear-cell mRCC. However, these findings should be interpreted in the context of the retrospective study design, potential selection bias, and lack of granular systemic therapy data within the NCDB.
- Open Access
Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022)
Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access to effective treatment remains a critical public health priority. Unequal access to definitive surgical management among disadvantaged populations may contribute to preventable morbidity and mortality. Radical prostatectomy is a cornerstone treatment for localized disease; however, its utilization has evolved over time in response to changing screening guidelines, technological advancements, and shifting treatment paradigms. Despite these developments, disparities in access to surgical management persist. Methods: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort study evaluating factors associated with radical prostatectomy utilization among 917,194 men with localized or regional prostate cancer diagnosed between 2004 and 2022. Multivariable logistic regression assessed demographic, socioeconomic, and clinical predictors of surgical treatment. Results: Overall, 33.5% of patients underwent radical prostatectomy. Increasing age was strongly associated with lower odds of surgery (OR 0.904 per year, 95% CI 0.903–0.904, p < 0.001), while married patients were significantly more likely to undergo prostatectomy (OR 1.601, 95% CI 1.554–1.649, p < 0.001). Black patients had markedly lower odds of surgery compared with White patients (OR 0.547, 95% CI 0.539–0.555, p < 0.001), whereas Asian/Pacific Islander patients had slightly higher odds (OR 1.082, p < 0.001). More recent year of diagnosis and increasing income were associated with modest reductions in prostatectomy utilization. Conclusions: These findings demonstrate that treatment selection in prostate cancer is influenced not only by disease characteristics but also by sociodemographic factors, highlighting persistent disparities in access to definitive surgical care and the need for targeted interventions to improve equity in treatment delivery.
Open AccessClinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022)
Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access to effective treatment remains a critical public health priority. Unequal access to definitive surgical management among disadvantaged populations may contribute to preventable morbidity and mortality. Radical prostatectomy is a cornerstone treatment for localized disease; however, its utilization has evolved over time in response to changing screening guidelines, technological advancements, and shifting treatment paradigms. Despite these developments, disparities in access to surgical management persist. Methods: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort study evaluating factors associated with radical prostatectomy utilization among 917,194 men with localized or regional prostate cancer diagnosed between 2004 and 2022. Multivariable logistic regression assessed demographic, socioeconomic, and clinical predictors of surgical treatment. Results: Overall, 33.5% of patients underwent radical prostatectomy. Increasing age was strongly associated with lower odds of surgery (OR 0.904 per year, 95% CI 0.903–0.904, p < 0.001), while married patients were significantly more likely to undergo prostatectomy (OR 1.601, 95% CI 1.554–1.649, p < 0.001). Black patients had markedly lower odds of surgery compared with White patients (OR 0.547, 95% CI 0.539–0.555, p < 0.001), whereas Asian/Pacific Islander patients had slightly higher odds (OR 1.082, p < 0.001). More recent year of diagnosis and increasing income were associated with modest reductions in prostatectomy utilization. Conclusions: These findings demonstrate that treatment selection in prostate cancer is influenced not only by disease characteristics but also by sociodemographic factors, highlighting persistent disparities in access to definitive surgical care and the need for targeted interventions to improve equity in treatment delivery.
- Open Access
Sociodemographic Factors and Treatment Patterns Associated with Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000–2022)
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population-level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan–Meier and Cox regression. Results: The cohort included 3548 patients (mean age: 68.2 years; 53.6% female). Most were White (89.8%) and non-Hispanic (92.1%). The Ann Arbor stage was missing in 39.4%. Treatment included systemic antineoplastic therapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow-up, 56.8% were alive; non-Hodgkin lymphoma accounted for 15.8% deaths in the cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.082 per year, 95% CI 1.072–1.091), male sex (HR 1.34, 95% CI 1.14–1.57), Hispanic ethnicity (HR 1.42, 95% CI 1.08–1.88), systemic antineoplastic therapy (HR 1.42, 95% CI 1.18–1.70), divorced/separated marital status vs. married (HR 1.35, 95% CI 1.03–1.77), and stage IV disease (HR 1.70, 95% CI 1.16–2.50). Race and year of diagnosis were not independently associated with OS in the adjusted model. Conclusions: In our large population-based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.
Open AccessSociodemographic Factors and Treatment Patterns Associated with Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000–2022)
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population-level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan–Meier and Cox regression. Results: The cohort included 3548 patients (mean age: 68.2 years; 53.6% female). Most were White (89.8%) and non-Hispanic (92.1%). The Ann Arbor stage was missing in 39.4%. Treatment included systemic antineoplastic therapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow-up, 56.8% were alive; non-Hodgkin lymphoma accounted for 15.8% deaths in the cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.082 per year, 95% CI 1.072–1.091), male sex (HR 1.34, 95% CI 1.14–1.57), Hispanic ethnicity (HR 1.42, 95% CI 1.08–1.88), systemic antineoplastic therapy (HR 1.42, 95% CI 1.18–1.70), divorced/separated marital status vs. married (HR 1.35, 95% CI 1.03–1.77), and stage IV disease (HR 1.70, 95% CI 1.16–2.50). Race and year of diagnosis were not independently associated with OS in the adjusted model. Conclusions: In our large population-based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.
- Open Access
- 14 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4) , e72527
Pre‐Emptive Amlodipine for FOLFIRINOX ‐Induced Hypertensive Crises Without Primary Hypertension: A Novel Chronotherapeutic Strategy
FOLFIRINOX remains a cornerstone therapy for advanced pancreatic ductal adenocarcinoma (PDAC), but its toxicity profile extends beyond myelosuppression and neuropathy to include even rarer complications such as treatment‐associated hypertension. Infusion‐related hypertensive episodes represent a clinically challenging and underrecognized complication, as conventional daily antihypertensive strategies may control acute elevations yet precipitate inter‐cycle hypotension. We describe a 46‐year‐old woman with metastatic PDAC who developed recurrent hypertensive crises (peak 190/102 mmHg) temporally associated with FOLFIRINOX infusions. A trial of daily losartan (50 mg) mitigated infusion‐related hypertension but resulted in symptomatic inter‐cycle hypotension, limiting dose escalation. To better align antihypertensive therapy with the predictable timing of blood pressure surges, a chronotherapeutic strategy was implemented using low‐dose daily losartan (25 mg) combined with a single pre‐emptive dose of amlodipine (5 mg) administered 8–12 h prior to chemotherapy infusion after informed decision‐making. This approach resulted in consistent control of infusion‐related blood pressure elevations (systolic ~125–145 mmHg during treatment), elimination of hypertensive crises, and maintenance of stable inter‐cycle hemodynamics without symptomatic hypotension. Importantly, this strategy enabled uninterrupted delivery of full‐dose chemotherapy. This case highlights a novel, hypothesis‐generating chronotherapeutic approach to chemotherapy‐induced hypertension. Timed antihypertensive administration may represent a targeted strategy to control infusion‐related blood pressure surges while preserving baseline hemodynamic stability; however, further validation in larger studies is required before clinical generalization.
- 14 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4) , e72527
Open AccessPre‐Emptive Amlodipine for FOLFIRINOX ‐Induced Hypertensive Crises Without Primary Hypertension: A Novel Chronotherapeutic Strategy
FOLFIRINOX remains a cornerstone therapy for advanced pancreatic ductal adenocarcinoma (PDAC), but its toxicity profile extends beyond myelosuppression and neuropathy to include even rarer complications such as treatment‐associated hypertension. Infusion‐related hypertensive episodes represent a clinically challenging and underrecognized complication, as conventional daily antihypertensive strategies may control acute elevations yet precipitate inter‐cycle hypotension. We describe a 46‐year‐old woman with metastatic PDAC who developed recurrent hypertensive crises (peak 190/102 mmHg) temporally associated with FOLFIRINOX infusions. A trial of daily losartan (50 mg) mitigated infusion‐related hypertension but resulted in symptomatic inter‐cycle hypotension, limiting dose escalation. To better align antihypertensive therapy with the predictable timing of blood pressure surges, a chronotherapeutic strategy was implemented using low‐dose daily losartan (25 mg) combined with a single pre‐emptive dose of amlodipine (5 mg) administered 8–12 h prior to chemotherapy infusion after informed decision‐making. This approach resulted in consistent control of infusion‐related blood pressure elevations (systolic ~125–145 mmHg during treatment), elimination of hypertensive crises, and maintenance of stable inter‐cycle hemodynamics without symptomatic hypotension. Importantly, this strategy enabled uninterrupted delivery of full‐dose chemotherapy. This case highlights a novel, hypothesis‐generating chronotherapeutic approach to chemotherapy‐induced hypertension. Timed antihypertensive administration may represent a targeted strategy to control infusion‐related blood pressure surges while preserving baseline hemodynamic stability; however, further validation in larger studies is required before clinical generalization.
- Open Access
- 8 April 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (1) , 245-257
Platelet Transfusion Is Associated With Increased Thrombosis and In‐Hospital Mortality Among Patients Hospitalized With Platelet Consumptive Disorders
Background: Platelet transfusion is commonly used to reduce bleeding risk in platelet consumptive disorders. However, platelets may also promote thromboinflammatory pathways, and contemporary data evaluating the association between platelet transfusion, thrombosis, and mortality in this population are limited. Methods: We performed a retrospective cohort study using the National Inpatient Sample from 2018 to 2021. Non‐elective hospitalizations with immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, heparin‐induced thrombocytopenia, or other primary thrombocytopenias were included. The exposure was receipt of any platelet transfusion during hospitalization. Primary outcomes were in‐hospital mortality and in‐hospital thrombotic events, defined as venous thromboembolism or arterial thrombosis using ICD‐10‐CM codes. Inverse probability of treatment weighting and survey‐weighted logistic regression were used to adjust for demographics, comorbidities, illness severity, major bleeding, and disease‐specific therapies. Results: Among 67 405 hospitalizations (337 705 weighted national estimates), 10.5% received platelet transfusion. Mortality was higher in transfused versus nontransfused hospitalizations (9.5% vs. 6.1%; p < 0.001). After adjustment, platelet transfusion was associated with increased odds of in‐hospital mortality (adjusted odds ratio [aOR], 1.42; 95% CI: 1.28–1.60) and thrombosis (any thrombosis: aOR, 1.28; 95% CI: 1.18–1.39). Associations were observed for venous (aOR, 1.39) and arterial thrombosis (aOR, 1.15). Thrombotic risk persisted among hospitalizations without major bleeding but was attenuated with major bleeding. Intravenous immunoglobulin was associated with higher odds of thrombosis, while plasma exchange was associated with lower odds. Conclusion: In patients hospitalized with platelet consumptive disorders, platelet transfusion was associated with higher odds of in‐hospital thrombosis and mortality, supporting judicious, indication‐driven transfusion practices.
- 8 April 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (1) , 245-257
Open AccessPlatelet Transfusion Is Associated With Increased Thrombosis and In‐Hospital Mortality Among Patients Hospitalized With Platelet Consumptive Disorders
Background: Platelet transfusion is commonly used to reduce bleeding risk in platelet consumptive disorders. However, platelets may also promote thromboinflammatory pathways, and contemporary data evaluating the association between platelet transfusion, thrombosis, and mortality in this population are limited. Methods: We performed a retrospective cohort study using the National Inpatient Sample from 2018 to 2021. Non‐elective hospitalizations with immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, heparin‐induced thrombocytopenia, or other primary thrombocytopenias were included. The exposure was receipt of any platelet transfusion during hospitalization. Primary outcomes were in‐hospital mortality and in‐hospital thrombotic events, defined as venous thromboembolism or arterial thrombosis using ICD‐10‐CM codes. Inverse probability of treatment weighting and survey‐weighted logistic regression were used to adjust for demographics, comorbidities, illness severity, major bleeding, and disease‐specific therapies. Results: Among 67 405 hospitalizations (337 705 weighted national estimates), 10.5% received platelet transfusion. Mortality was higher in transfused versus nontransfused hospitalizations (9.5% vs. 6.1%; p < 0.001). After adjustment, platelet transfusion was associated with increased odds of in‐hospital mortality (adjusted odds ratio [aOR], 1.42; 95% CI: 1.28–1.60) and thrombosis (any thrombosis: aOR, 1.28; 95% CI: 1.18–1.39). Associations were observed for venous (aOR, 1.39) and arterial thrombosis (aOR, 1.15). Thrombotic risk persisted among hospitalizations without major bleeding but was attenuated with major bleeding. Intravenous immunoglobulin was associated with higher odds of thrombosis, while plasma exchange was associated with lower odds. Conclusion: In patients hospitalized with platelet consumptive disorders, platelet transfusion was associated with higher odds of in‐hospital thrombosis and mortality, supporting judicious, indication‐driven transfusion practices.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (2) , 104
The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers
The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers
- 1 April 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (2) , 104
Open AccessThe underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers
The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers